NVO - Xeris: Looking For Entry Before PDUFA

Xeris Pharmaceuticals (XERS) is developing a resolution to a major dilemma in the diabetic population using their exclusive technologies for the delivery of ready-to-use, room temperature stable formulations.

Although Xeris is a recent IPO, the company's researchers have been hard at work for over a decade developing these unique formulations. Their tireless attempts eventually created the XeriSol technology, which ultimately led to the first room temperature liquid stable glucagon. Prior to XeriSol technology, a ready-to-use glucagon formulation was an obstacle due to the glucagon peptide being unstable in water. Xeris